{"id":"adcld-cov19-1-omi","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain or erythema"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Myalgia"}]},"_chembl":{"chemblId":"CHEMBL401093","moleculeType":"Small molecule","molecularWeight":"374.44"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This vaccine uses a replication-deficient adenoviral vector to deliver genetic material encoding Omicron variant spike protein or related antigens, triggering both cellular and humoral immune responses. The adenoviral platform is designed to stimulate T-cell and B-cell immunity to provide protection against COVID-19 infection and severe disease caused by Omicron and related variants.","oneSentence":"AdCLD-CoV19-1 OMI is an adenoviral vector-based vaccine designed to elicit immune responses against Omicron variant SARS-CoV-2 antigens.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:59:39.375Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"COVID-19 prevention (Omicron variant)"}]},"trialDetails":[{"nctId":"NCT05993325","phase":"PHASE3","title":"Immunogenicity and Safety of AdCLD-CoV19-1 OMI As a Booster: a COVID-19 Preventive Vaccine in Healthy Volunteers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cellid Co., Ltd.","startDate":"2023-11-27","conditions":"COVID-19, Vaccines","enrollment":4000},{"nctId":"NCT05576623","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of AdCLD-CoV19-1 OMI as a Booster: A SARS-CoV-2 (COVID-19) Preventive Vaccine","status":"COMPLETED","sponsor":"Cellid Co., Ltd.","startDate":"2022-09-14","conditions":"COVID-19, Vaccines","enrollment":320}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"AdCLD-CoV19-1 OMI","genericName":"AdCLD-CoV19-1 OMI","companyName":"Cellid Co., Ltd.","companyId":"cellid-co-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"AdCLD-CoV19-1 OMI is an adenoviral vector-based vaccine designed to elicit immune responses against Omicron variant SARS-CoV-2 antigens. Used for COVID-19 prevention (Omicron variant).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}